Clinical Research Studies
Search our active and enrolling clinical research studies and see if you may qualify to participate.
This is a study in adults who had a heart attack (myocardial infarction). The purpose of this study is to find out whether a medicine called empagliflozin helps to lower the chances of having to go to the hospital for heart failure and whether it lowers the chances of dying from cardiovascular disease.
This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example, heart attack and stroke) in people with cardiovascular disease, chronic kidney disease and inflammation.
Participants will either receive ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). This is known as the study medicine. Which treatment a participant receives is decided by chance. Participant's chance of getting ziltivekimab or placebo is the same.
The aim of the TARGET-IV NA trial is to demonstrate the clinical non-inferiority of the Firehawk® rapamycin eluting stent system in comparison to currently approved 2nd generation DES for the treatment of subjects with ischemic heart disease (NSTEMI, recent STEMI (>24 hours from initial presentation and in whom enzyme levels have peaked), unstable angina, and stable coronary disease), with atherosclerotic target lesion(s) in coronary arteries with visually estimated reference vessel diameters ≥2.25 mm and ≤4.0 mm.